10.1016/S0360-3016(99)00364-8-Reference-Cited by-同舟云学术

10.1016/S0360-3016(99)00364-8

Published:2000-01 Issue:2 Volume:46 Page:516-517
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Medicine University of Wisconsin School of

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference15 articles.

1. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung;Cox;Int J Radiat Oncol Biol Phys,1993

2. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the respiratory/digestive tracts;Cox;New evidence for accelerated proliferation from RTOG Protocol 83-13. Cancer,1992

3. Local control versus dose or overall time;Fowler;Br J Radiol,1994

4. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy;Hendry;Clin Oncol,1996

5. The influence of number of fractions and of overall time on local control and late complications in squamous cell carcinoma of the larynx;Maciejewski;Int J Radiat Oncol Biol Phys,1983

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer;JAMA Oncology;2024-01-11

2. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms;Pneumologie;2023-10

3. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-09

4. Early Non-small Cell Lung Cancer: The Place of Radical Non-SABR Radiation Therapy;Medical Radiology;2023

5. The critical components for effective adaptive radiotherapy in patients with unresectable non-small-cell lung cancer: who, when and how;Future Oncology;2022-10